East China Pharmaceutical: Some products and collaborative products included in the national medical insurance and commercial insurance innovative drug catalog.

East China Medicine announced that the National Medical Insurance Administration and the Ministry of Human Resources and Social Security have published a new version of the drug catalog and commercial insurance innovative drug catalog. Some of the company's products and cooperative products have been included. The fully-owned subsidiary Sinopharm East China's ustekinumab injection has been adjusted to the regular catalog management, with changes in the payment scope. Cooperative products such as senaparib capsules and lanthanum carbonate capsules have been included in the negotiated drugs within the agreement period, and ziv-aflibercept injection has been included in the commercial insurance innovative drug catalog. The new drug catalog will be implemented from 2026 onwards, and the inclusion of the aforementioned products will not have a significant impact on recent performance, but is expected to assist in future market promotion.